Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
A Study of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck with No Distant Metastases
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Rakuten Medical, Inc.
- Target Recruit Count
- 408
- Registration Number
- NCT06699212
- Locations
- 🇺🇸
Cancer Clinic, Lexington, Kentucky, United States
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Target Recruit Count
- 45
- Registration Number
- NCT06699498
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-20
- Target Recruit Count
- 60
- Registration Number
- NCT06696742
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT06694454
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
Phase 2
Not yet recruiting
- Conditions
- Interventions
- Drug: Albumin-Bound PaclitaxelDrug: OtherDrug: EpirubicinDrug: GemcitabineDrug: VinorelbineDrug: CisplatinDrug: IrinotecanDrug: FluorouracilDrug: NivolumabDrug: PembrolizumabDrug: DurvalumabDrug: AtezolizumabDrug: SintilimabDrug: TislelizumabDrug: CamrelizumabDrug: ToripalimabDrug: SerplulimabDrug: AdebrelimabDrug: EnvafolimabDrug: OsimertinibDrug: AlectinibDrug: VemurafenibDrug: PamiparibDrug: PyrotinibDrug: ImatinibDrug: PalbociclibDrug: SavolitinibDrug: Entrectinib
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Peking University Shenzhen Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06692491
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- mAbxience Research S.L.
- Target Recruit Count
- 726
- Registration Number
- NCT06687369
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Target Recruit Count
- 380
- Registration Number
- NCT06682611
Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT06659042
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-18
- Target Recruit Count
- 355
- Registration Number
- NCT06647563
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1100
- Registration Number
- NCT06632327
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath